MAPK8 and myeloproliferative neoplasm: In view of the promising data of reversine in MPN cellular models, and the opportunity to identify new potential targets for these diseases, the effects of additional selective inhibitors for AURKA, AURKB, MPS1, and JNK were tested and all this inhibitor reduced cell viability with differences in their potencies (Supplementary Fig. 6) Of note, JNK, AURK, and MPS1 signaling pathways present cross-talk contributing to cell cycle progression.